Table 1.
CTC detection and clinical characteristics of early breast cancer patients
| Patients enrolled | AdnaTest | CK19 | Multiplex | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| All number (%) |
Positive number (%) |
Negative number (%) |
Pa | Positive number (%) |
Negative number (%) |
Pa | Positive number (%) |
Negative number (%) |
Pa | |
| 254 (100) | 42 (16.5) | 212 (83.5) | 36 (14.2) | 218 (85.8) | 58 (22.8) | 196 (77.2) | ||||
| Age, years | 0.398 | 0.383 | 0.614 | |||||||
| ≥ 61 | 130 (51.2) | 24 (18.5) | 106 (81.5) | 16 (12.3) | 114 (87.7) | 28 (21.5) | 102 (78.5) | |||
| < 61 | 124 (48.8) | 18 (14.5) | 106 (85.5) | 20 (16.1) | 104 (83.9) | 30 (24.2) | 94 (75.8) | |||
| Staging | 0.827 | 0.343 | ||||||||
| Tx | 1 (0.39) | 0 (0) | 1 (100) | 0 (0) | 1 (100) | 0 (0) | 1 (100) | |||
| is | 8 (3.15) | 2 (25.0) | 6 (75.2) | 0 (0) | 8 (100) | 1 (12.5) | 7 (87.5) | |||
| To | 6 (2.36) | 1 (16.7) | 5 (83.3) | 0 (0) | 6 (100) | 2 (33.3) | 4 (66.7) | |||
| I/II | 206 (81.1) | 29 (14.1) | 177 (85.9) | 34 (16.5) | 172 (83.5) | 48 (23.3) | 158 (76.7) | |||
| III/IV | 19 (7.48) | 4 (21.1) | 15 (78.9) | 1 (5.26) | 18 (94.7) | 4 (21.0) | 15 (79.0) | |||
| Unknown | 14 (5.51) | |||||||||
| Grading | 0.386 | 0.822 | ||||||||
| 1 | 45 (17.7) | 5 (11.1) | 40 (88.9) | 6 (13.3) | 39 (86.7) | 12 (26.7) | 33 (73.3) | 0.816 | ||
| 2 | 105 (41.3) | 19 (18.1) | 86 (81.9) | 17 (16.2) | 88 (83.8) | 23 (21.9) | 82 (78.1) | |||
| 3 | 83 (32.7) | 10 (12.1) | 73 (88.0) | 11 (13.2) | 72 (86.8) | 19 (22.9) | 64 (77.1) | |||
| Unknown | 21 (8.37) | |||||||||
| Lymph nodes | ||||||||||
| N0 | 130 (51.2) | 17 (13.1) | 113 (86.9) | 0.099 | 23 (17.7) | 107 (82.3) | 0.450 | 31 (23.8) | 99 (76.2) | 0.871 |
| N1 | 54 (21.3) | 9 (16.7) | 45 (83.3) | 6 (11.1) | 48 (88.9) | 15 (27.8) | 39 (72.2) | |||
| N2 | 15 (5.91) | 3 (20.0) | 12 (80.0) | 2 (13.3) | 13 (86.7) | 3 (20.0) | 12 (80.0) | |||
| N3 | 6 (2.36) | 3 (50.0) | 3 (50.0) | 2 (33.3) | 4 (66.7) | 1 (16.7) | 5 (83.3) | |||
| Unknown | 49 (19.3) | |||||||||
| Histology | ||||||||||
| Ductal | 175 (68.9) | 23 (13.1) | 152 (86.9) | 0.251 | 23 (13.1) | 152 (86.9) | 0.201 | 39 (22.3) | 136 (77.7) | |
| Lobular | 35 (13.8) | 7 (20.0) | 28 (80.0) | 9 (25.7) | 26 (74.3) | 12 (34.3) | 23 (65.7) | |||
| Ductal/Lobular | 5 (1.97) | 2 (40.0) | 3 (60.0) | 1 (20.0) | 4 (80.0) | 0 (0) | 5 (100) | |||
| Other | 24 (9.45) | 5 (20.8) | 19 (79.2) | 2 (8.3) | 22 (91.7) | 4 (16.7) | 20 (83.3) | |||
| Unknown | 15 (5.91) | |||||||||
| ER | 0.553 | 0.275 | 0.581 | |||||||
| Positive | 179 (70.5) | 28 (15.6) | 151 (84.4) | 29 (16.2) | 150 (83.8) | 40 (22.3) | 139 (77.7) | |||
| Negative | 58 (22.8) | 11 (19.0) | 47 (81.0) | 6 (10.3) | 52 (89.7) | 15 (25.9) | 43 (74.1) | |||
| Unknown | 17 (6.7) | |||||||||
| PR | 0.474 | 0.184 | 0.361 | |||||||
| Positive | 175 (68.9) | 27 (15.4) | 148 (84.6) | 29 (16.6) | 146 (83.4) | 38 (21.7) | 137 (78.3) | |||
| Negative | 62 (24.4) | 12 (19.4) | 50 (80.6) | 6 (9.7) | 56 (90.3) | 17 (27.4) | 45 (72.6) | |||
| Unknown | 17 (6.7) | |||||||||
| HER2 | 0.725 | 0.397 | ||||||||
| Positive | 38 (15.0) | 7 (18.4) | 31 (81.6) | 0.639 | 5 (13.2) | 33 (86.8) | 11 (29.0) | 27 (71.0) | ||
| Negative | 195 (76.8) | 30 (15.4) | 165 (84.6) | 30 (15.4) | 165 (84.6) | 44 (22.6) | 151 (77.4) | |||
| Unknown | 21 (8.27) | |||||||||
aChi-square test. ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PR, progesterone receptor.